MannKind reported $-15.95M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Adma Biologics USD 49.38M 12.95M Dec/2025
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Insmed USD -163.56M 164.92M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
MannKind USD -15.95M 23.93M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Novavax USD 17.53M 219.91M Dec/2025
Novo Nordisk DKK 4.03B 25.01B Jun/2025
Pfizer USD 2.69B 4.34B Mar/2026
Sanofi EUR 1.61B 2.42B Mar/2026
Xencor USD -128.92M 122.26M Mar/2026